- Cellistic has launched three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio and Echo™-Endothelial.
- The platforms are designed to support scalable development and manufacturing across immuno-oncology and regenerative medicine.
Cellistic has announced the launch of three new induced pluripotent stem cell (iPSC)-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio and Echo™-Endothelial. The platforms are intended to support the development and manufacturing of allogeneic cell therapies across immuno-oncology and regenerative medicine.
The new platforms build on the company’s existing Echo™-NK manufacturing platform for natural killer cells. Cellistic said the expanded Echo™ portfolio leverages its GMP manufacturing experience and its EMA-certified, FDA- and PMDA-compliant facility to deliver scalable manufacturing solutions across additional immune and regenerative cell types. The platforms are positioned to address scalability and manufacturability challenges that can limit patient access and programme viability.
According to the company, the platforms span the full development continuum for iPSC-derived cell therapies, from cell line generation through each unit operation required to produce the target cell type. This approach is designed to enable consistent progression from clinical development to commercial manufacturing within a CDMO and contract manufacturing framework.
“Building on this foundation and more than 15 years of experience in iPSC-derived cell therapy process development and GMP manufacturing, our team has developed three platforms designed to overcome the limitations of current cell therapy approaches.”
Gustavo Mahler, CEO of Cellistic
Cellistic stated that Echo™-T is designed to deliver iPSC-derived αβ T cells or regulatory T cells with defined phenotype and predictable immune function, Echo™-Cardio provides iPSC-derived cardiomyocytes for cardiac regenerative programmes, and Echo™-Endothelial delivers iPSC-derived endothelial cells to support therapies targeting vascular biology, inflammation and the tumour microenvironment. The company added that the platforms are already supporting multiple development programmes, including those approaching IND submission.
